Lomecel-B medicinal signaling cells

Phase 2Biologic

Lomecel-B medicinal signaling cells is one of 3 biologic programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypoplastic Left Heart SyndromeActive, not recruiting

Hypoplastic Left Heart SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Hypoplastic Left Heart Syndrome

#DrugCompanyPhaseTrials

Letairis

Tepadina

Lomecel-B medicinal signaling cells

LLongeveron Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoplastic Left Heart Syndrome1 trial

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Active, not recruiting·LLongeveron Inc.·Phase 2·NCT04925024·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lomecel-B medicinal signaling cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lomecel-B medicinal signaling cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lomecel-B medicinal signaling cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Longeveron Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: LLongeveron Inc.

Lomecel-B medicinal signaling cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoplastic Left Heart Syndrome1 trial

References

Drug Info

Quick Facts

Related News